Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzyme replacement royalties, gene-therapy milestone payments, and orphan-drug pricing updates make BioMarin Pharmaceutical鈥檚 SEC disclosures uniquely complex. Finding the R&D footnotes that explain trial costs or the revenue breakout for therapies like Voxzogo can take hours.
Stock Titan solves that problem. Our AI reads every BioMarin document on EDGAR鈥�10-Ks, 10-Qs, 8-Ks, S-8s, and especially Form 4 insider filings鈥攁nd produces plain-English briefs. Use it for BioMarin SEC filings explained simply or to dive deeper with red-line comparisons and keyword search. Whether you need the latest BioMarin quarterly earnings report 10-Q filing or an older BioMarin annual report 10-K simplified, you鈥檒l get both the full PDF and an AI summary that flags pipeline milestones and revenue drivers.
AG真人官方-time alerts track BioMarin Form 4 insider transactions real-time, giving you instant visibility into executive stock moves. Curious about compensation? The platform links directly to the BioMarin proxy statement executive compensation section, while our explanations spotlight option grants and performance metrics. For sudden developments, the system pushes notifications with BioMarin 8-K material events explained鈥攆rom FDA feedback to collaboration agreements鈥攕o you never miss market-moving news.
Practical use cases include monitoring BioMarin insider trading Form 4 transactions before trial readouts, comparing quarter-over-quarter R&D spend through our BioMarin earnings report filing analysis, and understanding BioMarin SEC documents with AI when assessing long-term cash burn. All filings update the moment they hit EDGAR, giving analysts, portfolio managers, and biotech enthusiasts a single source for accurate, timely disclosure intelligence.
Nurix Therapeutics, Inc. (NRIX) has filed a Form 144 disclosing that shareholder Johannes Van Houte plans to sell 5,402 common shares through Morgan Stanley Smith Barney, with an approximate market value of $60,826.52. The transaction is expected on or about 01 Aug 2025 on the NASDAQ. With 76,449,355 shares outstanding, the proposed sale equals roughly 0.007 % of the company鈥檚 equity.
The notice also lists two prior sales in the last three months: 4,304 shares on 30 Jul 2025 for $51,695.34 and 6,198 shares on 02 May 2025 for $70,242.55鈥攖ogether totaling 10,502 shares and $121,938. These shares, like the new lot, originated from restricted stock units acquired on 30 Jul 2025. The filer attests to possessing no undisclosed material adverse information and may be trading under a Rule 10b5-1 plan, indicating procedural compliance rather than a sudden shift in outlook.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
What is BioMarin Pharmaceutical Inc.'s primary focus?
What types of therapies does BioMarin develop?
How does BioMarin drive innovation in the biotechnology sector?
What distinguishes BioMarin from other pharmaceutical companies?
How extensive is BioMarin's research and development framework?
What role does operational efficiency play in BioMarin's strategy?
How does BioMarin address the needs of rare disease patient populations?
In what ways is BioMarin positioned in the competitive landscape?
